Abstract
AbstractThe physiological links between abnormalities in glucose regulation and blood pressure provide novel means to treat patients with the Metabolic Syndrome. In fact, recent data indicate that ATR1 antagonists may also improve insulin resistance. We explored one proposed explanation for these effects, namely activation of the PPARγ nuclear hormone receptor. These studies should guide further efforts to develop agents to treat hypertension and insulin resistance. Drug Dev. Res. 67:579–581, 2006. © 2006 Wiley‐Liss, Inc.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
